^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

livmoniplimab (ABBV-151)

i
Other names: ABBV-151, ARGX 115, ARGX-115, ABBV 151
Associations
Trials
Company:
AbbVie, argenx
Drug class:
TGF-β1 inhibitor, LRRC32 inhibitor
Associations
Trials
1m
New P2 trial
|
gemcitabine • paclitaxel • docetaxel • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
2ms
Enrollment closed • Adverse events • Combination therapy • Checkpoint inhibition • Metastases
|
sorafenib • Lenvima (lenvatinib) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
2ms
Enrollment open • Adverse events • Combination therapy • Checkpoint inhibition • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
4ms
New P1 trial • Adverse events • Combination therapy • Checkpoint inhibition • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
7ms
Trial primary completion date • Combination therapy • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
8ms
Enrollment open • Adverse events • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
8ms
Trial completion date • Combination therapy • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
9ms
New P2/3 trial • Adverse events • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
11ms
Enrollment open • Phase classification • Adverse events • Combination therapy • Metastases
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
1year
New P2 trial • Adverse events • Combination therapy • Metastases
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
1year
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
3years
Clinical • Enrollment change • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
3years
Clinical • Trial completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
over4years
Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
TGFB1 (Transforming Growth Factor Beta 1)
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)